Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Sep
17
Today In Oncology
AI’s Evolving Role in Clinical Care Enterprise-Wide
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Zipalertinib Added to Chemotherapy Improves PFS in First-Line EGFR Exon 20 NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo